Small area variation and geographic and patient‐specific determinants of metabolic testing in antipsychotic users

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2011-01-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1002/pds.2062PMID 21182154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists.

  2025cited by this paper
• Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.

  2010cited by this paper
• Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

  2010cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Slowing the growth of health care costs--lessons from regional variation.

  2009cited by this paper
• Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes

  2009cited by this paper
• Standards of Medical Care in Diabetes—2009

  2009cited by this paper
• Standards of medical care in diabetes--2007.

  2009cited by this paper
• Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

  2009cited by this paper
• Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients

  2008cited by this paper
• Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

  2008cited by this paper
• Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.

  2008cited by this paper
• Prioritizing Future Research on Off‐Label Prescribing: Results of a Quantitative Evaluation

  2008cited by this paper
• Lipid Screening and Cardiovascular Health in Childhood

  2008cited by this paper
• Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

  2008cited by this paper
• Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

  2008cited by this paper
• Severe mental illness and risk of cardiovascular disease.

  2007cited by this paper
• Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice

  2006cited by this paper
• The Metabolic Effects of Antipsychotic Medications

  2006cited by this paper
• Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States

  2006cited by this paper
• Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001.

  2005cited by this paper
• Estimating medication persistency using administrative claims data.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Physical health monitoring of patients with schizophrenia.

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Geography and the debate over Medicare reform.

  2002cited by this paper
• Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

  2002cited by this paper
• Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities

  2001cited by this paper
• A Population‐Based Health Information System

  1995cited by this paper
• Small-area variations: what are they and what do they mean? Health Services Research Group.

  1992cited by this paper
• Small area variations in health care delivery

  1992cited by this paper
• What is too much variation? The null hypothesis in small-area analysis.

  1990cited by this paper
• Dealing with medical practice variations: a proposal for action.

  1984cited by this paper
• Small Area Variations in Health Care Delivery

  1973cited by this paper

• A scoping review of cardiovascular risk factor screening rates in general or family practice attendees living with severe mental ill-health.

  2023cites this paper
• Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data

  2021cites this paper
• Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers.

  2019cites this paper
• Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness

  2017cites this paper
• First- and Second-Generation Antipsychotics in

  2017cites this paper
• Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.

  2016cites this paper
• Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens

  2016cites this paper
• Psychotropic drug use among preschool children in the Medicaid program from 36 states.

  2015cites this paper
• Ensuring the Safety of Children Treated with Second-Generation Antipsychotics

  2015cites this paper
• Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.

  2015cites this paper
• Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System

  2015cites this paper
• The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics.

  2015cites this paper
• Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics.

  2015cites this paper
• Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence

  2015influential citation
• Adjusting for geographic variation in observational comparative effectiveness studies: a case study of antipsychotics using state Medicaid data

  2014cites this paper
• Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics.

  2014cites this paper
• Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics

  2014cites this paper
• MonitoringforMetabolicSide EffectsAmongOutpatientsWith DementiaReceivingAntipsychotics

  2014cites this paper
• Monitoring veterans for metabolic side effects when prescribing antipsychotics.

  2013cites this paper
• Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness

  2013cites this paper
• GEOGRAPHIC VARIATION IN HEALTH CARE SPENDING AND UTILIZATION IN SUBGROUPS: MEDICAID, UNINSURED, AND UNDOCUMENTED POPULATIONS

  2013cites this paper
• Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics

  2013cites this paper
• An update on lipid profile screening in second-generation antipsychotic users in the USA

  2012cites this paper
• Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting.

  2012cites this paper
• Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory

  2012cites this paper
• Recent Advances in Understanding and Mitigating Adipogenic and Metabolic Effects of Antipsychotic Drugs

  2012cites this paper
• Authors' response: How can we produce relevant information for decision makers from small area variation studies?

  2011cites this paper
• Re: How can we produce relevant information for decision makers from small area variation studies?

  2011cites this paper